CN107840826A - 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor - Google Patents
1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor Download PDFInfo
- Publication number
- CN107840826A CN107840826A CN201610831550.7A CN201610831550A CN107840826A CN 107840826 A CN107840826 A CN 107840826A CN 201610831550 A CN201610831550 A CN 201610831550A CN 107840826 A CN107840826 A CN 107840826A
- Authority
- CN
- China
- Prior art keywords
- compound
- indazole
- nmr
- ppm
- ido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title description 2
- 229910052760 oxygen Inorganic materials 0.000 title description 2
- 239000001301 oxygen Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000005934 immune activation Effects 0.000 claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 208000002177 Cataract Diseases 0.000 claims abstract description 4
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 4
- 208000030507 AIDS Diseases 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000007787 solid Substances 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 27
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 26
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 26
- 239000000243 solution Substances 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229960004799 tryptophan Drugs 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- AZOJNADMDJQIBV-UHFFFAOYSA-N 2,5-dimethyl-1,3-dinitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=C(C)C([N+]([O-])=O)=C1 AZOJNADMDJQIBV-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RGSIWCOYONWAJH-UHFFFAOYSA-N 2,5-dimethyl-3-nitroaniline Chemical compound CC1=CC(N)=C(C)C([N+]([O-])=O)=C1 RGSIWCOYONWAJH-UHFFFAOYSA-N 0.000 description 5
- UHMQLMVVZOTFDR-UHFFFAOYSA-N 4-nitro-6-(trifluoromethyl)-1h-indazole Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC2=C1C=NN2 UHMQLMVVZOTFDR-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- LRLRAYMYEXQKID-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)benzene Chemical compound CC1=CC=C(C(F)(F)F)C=C1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 4
- YKEVTSMJXUJEMX-UHFFFAOYSA-N 2-methyl-1,3-dinitro-5-(trifluoromethyl)benzene Chemical compound CC1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O YKEVTSMJXUJEMX-UHFFFAOYSA-N 0.000 description 4
- QAKVILZRKISYBX-UHFFFAOYSA-N 2-methyl-3-nitro-5-(trifluoromethyl)aniline Chemical compound CC1=C(N)C=C(C(F)(F)F)C=C1[N+]([O-])=O QAKVILZRKISYBX-UHFFFAOYSA-N 0.000 description 4
- IHQAYTCBMNCOKS-UHFFFAOYSA-N 6-(trifluoromethyl)-1h-indazol-4-amine Chemical compound NC1=CC(C(F)(F)F)=CC2=C1C=NN2 IHQAYTCBMNCOKS-UHFFFAOYSA-N 0.000 description 4
- DLKUQAHLXGZFPM-UHFFFAOYSA-N 6-methyl-4-nitro-1h-indazole Chemical compound CC1=CC([N+]([O-])=O)=C2C=NNC2=C1 DLKUQAHLXGZFPM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 3
- AHEMYGJJCOXPSP-UHFFFAOYSA-N 6-bromo-4-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC(Br)=CC2=C1C=NN2 AHEMYGJJCOXPSP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- MAACLNKBFOTDTC-UHFFFAOYSA-N 6-bromo-N-[(4-nitrophenyl)methyl]-1H-indazol-4-amine Chemical compound BrC=1C=C(C=2C=NNC=2C=1)NCC1=CC=C(C=C1)[N+](=O)[O-] MAACLNKBFOTDTC-UHFFFAOYSA-N 0.000 description 2
- ALKXLVRDXHYCOA-UHFFFAOYSA-N 6-chloro-4-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC(Cl)=CC2=C1C=NN2 ALKXLVRDXHYCOA-UHFFFAOYSA-N 0.000 description 2
- JGZBDXTVJJTZOR-UHFFFAOYSA-N 6-methyl-1h-indol-4-amine Chemical compound CC1=CC(N)=C2C=CNC2=C1 JGZBDXTVJJTZOR-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- -1 Dihydropyridine ester Chemical class 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- 0 *c1cc([n]nc2)c2c(*)c1 Chemical compound *c1cc([n]nc2)c2c(*)c1 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- OOKFCQHMHNKVKJ-UHFFFAOYSA-N 5-bromo-2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=C(Br)C=C1[N+]([O-])=O OOKFCQHMHNKVKJ-UHFFFAOYSA-N 0.000 description 1
- JWKMYCQSTYOSPG-UHFFFAOYSA-N 6-(trifluoromethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-indazol-4-amine Chemical compound FC(C=1C=C(C=2C=NNC=2C=1)NCC1=CC(=CC=C1)C(F)(F)F)(F)F JWKMYCQSTYOSPG-UHFFFAOYSA-N 0.000 description 1
- XHWQIUNDWUOLTJ-UHFFFAOYSA-N 6-bromo-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-indazol-4-amine Chemical compound BrC=1C=C(C=2C=NNC=2C=1)NCC1=CC(=CC=C1)C(F)(F)F XHWQIUNDWUOLTJ-UHFFFAOYSA-N 0.000 description 1
- KGBIIGJZQFBLNK-UHFFFAOYSA-N 6-chloro-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-indazol-4-amine Chemical compound ClC=1C=C(C=2C=NNC=2C=1)NCC1=CC(=CC=C1)C(F)(F)F KGBIIGJZQFBLNK-UHFFFAOYSA-N 0.000 description 1
- JSJFMSSJOPVGAA-UHFFFAOYSA-N CC(Cc1cc(NCC(C=C2)=CCC2O)c(cn[nH]2)c2c1)N Chemical compound CC(Cc1cc(NCC(C=C2)=CCC2O)c(cn[nH]2)c2c1)N JSJFMSSJOPVGAA-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001248537 Eurema daira Species 0.000 description 1
- MAZDHTQQFZZMRB-UHFFFAOYSA-N FC(c1cc([nH]nc2)c2c(NCc2c(cc[s]3)c3ccc2)c1)(F)F Chemical compound FC(c1cc([nH]nc2)c2c(NCc2c(cc[s]3)c3ccc2)c1)(F)F MAZDHTQQFZZMRB-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a 1H-indazole derivative shown in a formula (I), and also discloses a preparation method of the compound and application of the compound as an IDO inhibitor. The compound of the present invention can be used for preventing and/or treating various diseases, such as Alzheimer disease, cataract, infection related to cell immune activation, autoimmune disease, AIDS, cancer, depression or tryptophan metabolism disorder, etc.
Description
Technical Field
The invention relates to 1H-indazole derivatives, a preparation method thereof and application thereof as IDO inhibitors.
Background
Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme which catalyzes the epoxidation and cleavage of indole in Indoleamine molecules such as tryptophan and the like so as to decompose and metabolize the indole according to the canine uric acid pathway.
IDO plays an important role in the process of tumor immune exemption and tumorigenesis. Under normal conditions, IDO is expressed at a low level in vivo, most tumor cells form high-expression IDO, L-tryptophan is converted into N-formyl kynurenine, the tryptophan concentration in the microenvironment of the cells is reduced, the synthesis of tryptophan-dependent T cells is stopped at G1, and the proliferation of the T cells is inhibited, so that the killing effect of the immune system of the body on tumor tissues is inhibited. Meanwhile, the metabolite of tryptophan has cytotoxicity under the action of IDO, and can directly dissolve T cells.
Therefore, inhibiting the activity of IDO can effectively prevent the degradation of tryptophan around tumor cells and promote the proliferation of T cells, thereby enhancing the attack capability of the body on the tumor cells. Moreover, the IDO inhibitor can be used together with chemotherapeutic drugs to reduce drug resistance of tumor cells, thereby enhancing the antitumor activity of conventional cytotoxic therapy. The administration of an IDO inhibitor also enhances the therapeutic efficacy of the therapeutic vaccine in cancer patients.
Besides playing an important role in tumor cell resistance, IDO is also closely associated with the pathogenesis of a variety of diseases associated with cellular immune activation. IDO has been shown to be a target for serious diseases associated with cellular immune activation, such as infections, malignancies, autoimmune diseases, aids, and the like. Meanwhile, IDO inhibition is an important treatment strategy for patients suffering from nervous system diseases such as depression and Alzheimer's disease. Therefore, the IDO inhibitor has wide clinical application prospect.
Disclosure of Invention
In order to solve the problems, the invention provides a 1H-indazole derivative or a pharmaceutically acceptable salt or solvate thereof, wherein the structure of the compound is shown as the formula (I):
wherein,
R1selected from H, halogen, C1~C6Alkyl or C1~C6A haloalkyl group;
R2selected from substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl, each of which is independently substituted with one or more substituents selected from halogen, -NH2、-(CH2)aOH, -COOH, nitro, C1~C6Alkyl radical, C1~C6Haloalkyl, -CONH-R3or-NH-R4Substituted with the substituent(s);
R3is selected from C1~C6An alkyl group;
R4(ii) select-CH2COOH or 5-6 membered cycloalkyl or C1~C6Alkyl-substituted cycloalkyl groups;
a is 0 or 1.
Further, said R1Selected from H, Cl, Br, -CF3、-CHX2、-CH2X or-CH3。
Further, said C1~C6The alkyl group is selected from methyl.
Further, said C1~C6Haloalkyl is trifluoromethyl.
Further, the aryl is selected from phenyl, the heteroaryl is selected from benzothiophene, the cycloalkyl is selected from cyclohexyl, and the heterocyclic group is selected from a 4-6-membered nitrogen heterocyclic group.
Further, said R2Selected from one of the following groups:
further, the compound is selected from one of the following compounds:
the invention also provides the application of the compound shown in the formula (I), the compound shown in the formula (II), or the pharmaceutically acceptable salt, the prodrug or the solvate thereof in preparing IDO inhibitor medicines,
R1as defined above.
Further, the drug is a drug for preventing and/or treating alzheimer's disease, cataract, infection associated with cellular immune activation, autoimmune disease, aids, cancer, depression or tryptophan metabolism disorder.
The invention also provides a pharmaceutical composition, which is characterized in that: the compound or the pharmaceutically acceptable salt thereof is used as an active ingredient, and pharmaceutically acceptable auxiliary materials are added to prepare the preparation.
Said C is1~C6Alkyl isFinger C1、C2、C3、C4、C5、C6The alkyl group of (1) is a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl, hexyl, and the like.
In the present invention, the meanings of the acronyms are as follows:
and (3) DHP: 1,4-Dihydropyridine, Dihydropyridine ester.
DMF: dimethylformamide, Dimethylformamide.
DCC: dicyclohexylcarbodiimide (Dicyclohexylcarbodiimide).
DIBAL-H: diasobutylaluminum bydride, diisobutylaluminium hydride
DIEA: n, N-Diisopropylethylamine, N, N-Diisopropylethylamine.
EA: ethyl acetate, Ethyl acetate.
EDCI: 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride.
Et3N: triethylamine, Triethylamine.
HOBT: 1-Hydroxybenzotriazole, 1-Hydroxybenzotriazole.
HATU: 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethylurea hexafluorophosphate.
PE: petroleum ether, Petroleum ether.
TFA: tallow Fatty Acid, trifluoroacetic Acid.
THF: tetrahydrofuran, Tetrahydrofuran.
And (3) a molecular sieve.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
The reagents and starting materials were obtained from commercially available commercial sources, except for starting materials specifically labeled for the source, which were purchased from Douglas chemical company.
Example 1 Synthesis of intermediate starting Material
(1) Synthesis of 5a and 5b
Synthesis of 2, 5-dimethyl-1, 3-dinitrobenzene (2a)
After dissolving xylene (1a) (2.00mL, 16.23mmol) in 20mL concentrated sulfuric acid in a dry 50mL pear-shaped flask, potassium nitrate (4.91g, 48.68mmol) was slowly added under stirring at room temperature, and the reaction was stirred at room temperature for 2 hours, the reaction mixture was slowly poured into ice water, filtered, the cake was dried under vacuum, and purified by column chromatography (PE: EA 80:1) to obtain a pale yellow solid (2a) (1.62g, yield 51%). And (3) structural identification:1H-NMR(400MHz,CDCl3,ppm):δ13.0(br,1H,NH),7.42(s,2H,Ar-H),2.45(s,6H,CH3).ESI-MS:197.05[M+H].
synthesis of 2-methyl-5-trifluoromethyl-1, 3-dinitrobenzene (2b)
2-methyl-5-trifluoromethyl-1, 3-dinitrobenzene (2b) was prepared as a yellow solid in 75% yield according to the method for preparing 2, 5-dimethyl-1, 3-dinitrobenzene (2a) from 4-trifluoromethyl-toluene (1b) (CAS: 6140-17-6, available from Dougenok reagent). And (3) structural identification:1H-NMR(400MHz,CDCl3,ppm):δ13.0(br,1H,NH),8.29(s,2H,Ar-H),2.69(s,3H,CH3).ESI-MS:251.02[M+H].
synthesis of 2, 5-dimethyl-3-nitroaniline (3a)
2, 5-dimethyl-1, 3-dinitrobenzene (2a) (196.0mg,1.00mmol) was dissolved in MeOH (6mL) and dioxane (3mL), concentrated hydrochloric acid (0.60mL) and Fe (168.90mg,3.00mmol) were added, and the reaction was stirred to 80 ℃ for 12 h. Filtering, spin-drying the reaction solution, and saturating NaHCO3The pH of the solution is adjusted to 7-8, EA is extracted for three times, an organic layer is washed by saturated saline solution, dried by anhydrous magnesium sulfate and spin-dried to obtain a light yellow solid of 142.8mg with the yield of 86%.
Synthesis of 2-methyl-5-trifluoromethyl-3-nitroaniline (3b)
Following the procedure for the preparation of 5-bromo-2-methyl-3-nitroaniline (3a) in example 1, 2-methyl-5-trifluoromethyl-3-nitroaniline (3b) was prepared in the form of a yellow solid with a yield of 68%.
Synthesis of 6-methyl-4-nitro-1H-indazole (4a)
2, 5-dimethyl-3-nitroaniline (9a) (83.0mg,0.50mmol) was dissolved in glacial acetic acid (3mL) and NaNO was added2(69.0mg,1.00mmol) was dissolved in water (0.5mL) and NaNO was added with stirring at room temperature2Slowly dripping the aqueous solution into a glacial acetic acid solution of 2, 5-dimethyl-3-nitroaniline (3a), separating out solids, stirring at room temperature for reaction for 13h, pouring the reaction solution into ice water, filtering, and drying a filter cake in a vacuum drying oven for 12h to obtain 79.6mg of yellow solids with the yield of 90%. Purity 98% by HPLC; structure identificationDetermining:1H-NMR(400MHz,d6-DMSO,ppm):δ12.46(br,1H),8.20(s,1H),8.10(s,1H),7.87(s,1H),2.35(s,3H).ESI-MS:178.18[M+H].
synthesis of 6-trifluoromethyl-4-nitro-1H-indazole (4b)
According to the method for producing 6-bromo-4 nitro-1H-indazole (4a), 6-trifluoromethyl-4 nitro-1H-indazole (4b) was produced with a yield of 79%. Purity by HPLC was 98%. And (3) structural identification:1H-NMR(400MHz,d6-DMSO,ppm):δ12.46(br,1H),8.20(s,1H),8.12(s,1H),7.80(s,1H).ESI-MS:232.13[M+H].
synthesis of 6-methyl-1H-indol-4-amine (5a)
Dissolving 6-methyl-4-nitro-1H-indazole (4a) (50mg,0.28mmol) serving as a raw material in a mixed solvent of ethanol (2mL) and water (1mL), adding ammonium chloride (1.6mg,0.03mmol), adding iron powder (79.1mg,1.41mmol), heating to 80 ℃, stirring for reaction for 0.5H, filtering the reaction solution while hot, and washing filter residues with ethanol. The ethanol was removed under reduced pressure and the aqueous layer was extracted three times with EA. The combined organic phases were washed with saturated brine, dried over anhydrous magnesium sulfate, spun dry, and passed through a column (PE: EA ═ 10:1) to give 34.9mg of a pale yellow solid with a yield of 84%. Purity 98% by HPLC;1H-NMR(400MHz,d6-DMSO,ppm):δ12.46(br,1H),7.70(s,1H),7.16(s,1H),6.85(s,1H),4.60(br,2H),2.21(s,3H).ESI-MS:148.10[M+H].
synthesis of 6-trifluoromethyl-1H-indazol-4-amine (5b)
The compound 4-trifluoromethyl-toluene (4b) was used as the starting material. See compound 5a for compound 5 b. Yellow solid, yield 95%. Purity 98% by HPLC;1H-NMR(400MHz,CDCl3,ppm):δ13.0(br,1H,NH),8.10(s,1H,indazole-H),7.21(s,1H,indazole-H),6.58(s,1H,indazole-H),4.37(br,2H,NH2).ESI-MS:202.05[M+H].
(2) synthesis of 5c and 5d
The starting material 6-bromo-4-nitro-1H-indazole (4c) or 6-chloro-4-nitro-1H-indazole (4d) (8.26mmol, available from south Jiangsu Biotech Ltd.) was dissolved in a mixed solvent of ethanol (20mL) and water (10mL), ammonium chloride (221.5mg,4.13mmol) was added, a portion of iron powder (1.3g,23.46mmol) was added first, the temperature was raised to 80 ℃ and the reaction was stirred for 45 minutes, the remaining iron powder (1.0g,17.86mmol) was added and the reaction was stirred for 20 minutes. After TLC detection of the reaction completion of the starting material, the reaction solution was filtered while hot, and the residue was washed with ethanol (10 mL). Ethanol was removed under reduced pressure and the aqueous layer was extracted three times with EA (20 mL). The combined organic phases were washed with saturated brine, dried over anhydrous magnesium sulfate, spin-dried and column-chromatographed (PE: EA ═ 8:1) to give a pale yellow solid in 92-94% yield. The purity is 98% by HPLC; structural characterization of 5 c:1H-NMR(400MHz,d6-DMSO,ppm):δ12.46(br,1H),8.15(s,1H),7.56(s,1H),6.88(s,1H),5.80(br,2H).ESI-MS:213.05[M+H]structural characterization of 5 d:1H-NMR(400MHz,d6-DMSO,ppm):δ12.46(br,1H),8.14(s,1H),7.54(s,1H),6.89(s,1H),5.78(br,2H).ESI-MS:168.03[M+H].
example 2 Synthesis of Compounds N1, N2, N3, N4 and N5 of the invention
6-bromo-N- (3-trifluoromethylbenzyl) -1H-indazol-4-amine (N1).
Amine 5c (0.28mmol) and benzaldehyde 6(0.24mmol) were dissolved in dichloromethane (DCM, 3mL) and DHP (83.5mg,0.33mmol) and appropriate amount added(840.2mg), trifluoroacetic acid (TFA, 17.6 μ L,0.24mmol) was added dropwise thereto, the mixture was refluxed at 40 ℃ for 12 hours, and the reaction mixture was filtered, spin-dried, and subjected to column chromatography (PE: EA ═ 10:1) to obtain compound N1. The yield is 53.9%; a red powdered solid;1H-NMR(400MHz,d6-CDCl3,ppm):δ8.00(s,1H,indazole-H3),7.69(s,1H,Ar-H),7.63-7.50(m,3H,Ar-H),7.06(s,1H,Ar-H),6.34(s,1H,Ar-H),4.56(d,2H,J=4.4Hz,benzyl-CH2).13C-NMR(100MHz,d6-CDCl3,ppm):δ141.9,141.7,139.2,131.7,131.4,130.8,129.4,124.6,124.3,122.9,112.5,103.5,102.2,47.6.ESI-MS:370.01[M+H].
the corresponding aldehyde starting materials were selected and prepared in a similar manner to give compounds N2, N3, N4, N5, with the following results and characterization:
4- ((6-bromo-1H-indazol-4-amino) methyl) benzothiophene (N2), yield 31.8%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ14.09(s,1H,indazole-NH),7.90(d,1H,J=7.0Hz,Ar-H),7.80(d,1H,J=7.0Hz,Ar-H),7.48(s,1H,NH),7.44(s,1H,Ar-H),7.22(s,1H,Ar-H),6.70(s,1H,Ar-H),6.59(s,1H,Ar-H),4.76(d,2H,J=5.0Hz,benzyl-CH2).ESI-MS:356.99[M+H].
3- ((6-bromo-1H-indazol-4-amino) methyl) phenol (N3) yield 49.6%; a light yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ12.97(s,1H,indazole-NH),9.63(s,1H,OH),8.23(s,1H,indazole-H),7.12(t,2H,J=7.7Hz,NH),6.82-6.78(m,3H,Ar-H),6.03(d,1H,J=0.9Hz,Ar-H),5.77(s,1H,Ar-H),4.36(d,2H,J=5.8Hz,benzyl-CH2).13C-NMR(100MHz,d6-DMSO,ppm):δ158.0,143.2,141.4,132.6,129.9,121.8,118.0,115.3,114.2,114.0,112.6,101.1,100.1,46.3.ESI-MS:318.02[M+H].
4- ((6-bromo-1H-indazol-4-amino) methyl) benzyl alcohol (N4), yield 49.6%; a light yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ12.84(s,1H,indazole-NH),8.22(s,1H,indazole-H3),7.35-7.27(m,5H,Ar-H),6.82(s,1H,NH),6.03(d,1H,J=1.1Hz,Ar-H),5.15(s,1H,OH),4.47(s,2H,CH 2NH),4.42(s,2H,CH 2COOH).13C-NMR(100MHz,d6-DMSO,ppm):δ143.2,142.2,141.6,138.2,132.6,127.2,127.1,121.7,112.6,101.2,100.3,63.2,48.2.ESI-MS:332.03[M-H].
6-bromo-N- (4-nitrobenzyl) -1H-indazol-4-amine (N5) as a light brown solid; the yield is 63.1%;1H-NMR(400MHz,d6-DMSO,ppm):δ12.90(s,1H,indazole-NH),8.23(d,2H,J=3.8Hz,Ar-H),8.22(s,1H,indazole-H),7.65(d,2H,J=8.6Hz,Ar-H),7.48(s,1H,-NH),6.86(s,1H,Ar-H),6.01(s,1H,Ar-H),4.62(d,2H,J=4.8Hz,benzyl-CH2).13C-NMR(100MHz,d6-DMSO,ppm):δ148.5,147.8,147.0,142.7,132.5,128.5,124.1,121.7,112.6,101.3,45.8.ESI-MS:347.01[M+H].
example 3 Synthesis of Compounds N6 and N7 of the invention
4- ((6-methyl-1H-indazol-4-amino) methyl) benzoic acid (N6).
Compound N6 was synthesized in a similar manner to that in example 2, except that compound 5a was used instead of compound 5c, to give compound N6. The yield is 42.0%; a pale yellow powdery solid;1H-NMR(400MHz,d6-DMSO,ppm):δ12.72(s,2H,COOH and indazole-NH),8.12(s,2H,indazole-H3and NH),7.91(d,2H,J=8.1Hz,Ar-H),7.50(d,2H,J=8.1Hz,Ar-H),6.47(s,1H,Ar-H),5.77(s,1H,Ar-H),4.50(s,2H,benzyl-CH2),2.21(s,3H,CH3),ESI-MS:282.12[M+H].
4- ((6-methyl-1H-indazol-4-amino) methyl) benzyl alcohol (N7).
Selecting corresponding aldehyde raw materials, and preparing the compound N7 according to a similar method, wherein the yield is 53.7%; a pale yellow powdery solid;1H-NMR(400MHz,d6-DMSO,ppm):δ9.23(s,2H,indazole-NH and OH),8.12(s,1H,indazole-H),7.19(d,2H,J=8.4Hz,Ar-H),6.72(d,2H,J=8.4Hz,Ar-H),6.47(s,1H,Ar-H),5.87(s,1H,Ar-H),4.29(d,2H,J=8.4Hz,benzyl-CH2),4.29(s,3H,CH3).ESI-MS:254.12[M+H].
example 4 Synthesis of Compounds N8, N9, N10, N11 and N12 of the invention
6-trifluoromethyl-N- (3-trifluoromethylbenzyl) -1H-indazol-4-amine (N8).
Compound N1 was synthesized in a similar manner to that in example 2, except that compound 5b was used instead of compound 5c, to give compound N8. The yield is 34.5%; a yellow solid; 1H-NMR (400MHz, d 6-CDCl)3,ppm):δ10.92(s,1H,indazole-NH),8.11(s,1H,indazole-H3),7.72(s,1H,Ar-H),7.65-7.51(m,2H,Ar-H andNH),7.20(s,1H,Ar-H),6.41(s,1H,Ar-H),4.61(d,2H,J=5.2Hz,benzyl-CH2).13C-NMR(100MHz,d6-CDCl3,ppm):δ166.0,162.2,141.8,141.0,140.4,139.1,131.7,130.9,129.4,124.7,124.6,124.5,124.4,123.1,114.9,97.1,96.0,61.5.ESI-MS:360.09[M+H].
The corresponding aldehyde starting materials were selected and prepared in a similar manner to give compounds N9, N10, N11 and N12. The results and characterization were as follows:
4- ((6-trifluoromethyl-1H-indazol-4-amino) methyl) benzothiophene (N9), yield 54.7%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.21(s,1H,indazole-NH),8.37(s,1H,indazole-H3),7.88(d,1H,J=7.8Hz,Ar-H),7.78(d,1H,J=7.6Hz,Ar-H),7.60(s,1H,NH),7.05(s,1H,Ar-H),6.36(s,1H,Ar-H),4.82(d,2H,J=5.9Hz,benzyl-CH2).13C-NMR(100MHz,d6-DMSO,ppm):δ145.3,142.7,140.5,140.0,139.2,132.7,128.6,126.7,124.8,124.4,123.7,122.9,121.8,115.3,95.8,94.0,42.6.ESI-MS:348.07[M+H].
n-methyl-3- (((6-trifluoromethyl-1H-indol-4-) amino) methyl) benzamide (N10), yield 60.5%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.18(s,1H,indazole-NH),8.43(s,1H,CONH),8.37(s,1H,indazole-H),7.91(s,1H,Ar-H),7.72(d,1H,J=7.7Hz,Ar-H).7.55(d,1H,J=7.7Hz,Ar-H).7.46-7.41(m,2H,Ar-H),6.15(s,1H,Ar-H),4.55(d,2H,J=5.8Hz,benzyl-CH2),2.78(d,3H,J=4.5Hz,-CH3).13C-NMR(100MHz,d6-DMSO,ppm):δ167.1,143.1,140.5,140.1,135.2,132.7,130.2,128.6,125.9,124.0,115.1,95.4,93.7,46.5,31.1.ESI-MS:349.12[M+H].
(1S,2S) -2- ((6-bromo-1H-indazol-4-amino) methyl) cyclohexanol n11. yield 52.7%; a beige solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.10(s,1H,indazole-NH),8.34(s,1H,indazole-H),6.95(s,1H,Ar-H),6.27(s,1H,Ar-H)),3.69-3.65(m,1H,cyclohexanol-H),3.24-3.18(m,1H,cyclohexanol-H),2.98-2.92(m,1H,cyclohexanol-H),1.97-1.88(m,2H,CH2NH),1.59-0.98(m,8H,cyclohexanol-H).13C-NMR(100MHz,d6-DMSO,ppm):δ143.8,140.7,132.6,129.1,126.9,124.2,114.9,93.0,71.7,46.3,44.7,36.0,29.7,25.5,24.9.ESI-MS:314.15[M+H].
3- ((6-trifluoromethyl-1H-indazol-4-amino) methyl) benzoic acid (N12) yield 81.2%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.11(s,2H,COOH and indazole-NH),8.36(d,1H,J=0.6Hz,Ar-H),8.01(s,1H,Ar-H),7.84(d,1H,J=7.7Hz,Ar-H),7.66(d,1H,J=7.7Hz,Ar-H),7.51-7.46(m,2H,NH and Ar-H),7.00(s,1H,Ar-H),6.15(s,1H,Ar-H),4.58(d,2H,J=6.0Hz,).ESI-MS:336.09[M+H].
EXAMPLE 5 Synthesis of Compound N13 of the present invention
6-chloro-N- (3-trifluoromethylbenzyl) -1H-indazol-4-amine (N13).
Compound N13 was synthesized in a similar manner to that in example 2, except that compound 5d was used instead of compound 5c, to give compound N13. The yield is 58 percent; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ12.42(s,2H,COOH andindazole-NH),8.14(s,2H,indazole-H3and NH),8.05(d,2H,J=8.1Hz,Ar-H),7.76(d,2H,J=8.1Hz,Ar-H),6.58(s,1H,Ar-H),5.79(s,1H,Ar-H),4.58(s,2H,benzyl-CH2);ESI-MS:302.02[M+H].
EXAMPLE 6 Synthesis of Compound N14 of the present invention
Synthesis of Compound (9)
The raw material (5b) (150mg,0.746mmol) and the raw material (8) (185.4mg,0.896mmol) were dissolved in DCM (7mL), DHP (264.2mg,1.04mmol) was added thereto, trifluoroacetic acid (55.8uL,0.746mmol) was added dropwise, the reaction was refluxed at 40 ℃ for 12 hours, and the reaction mixture was filtered, dried by spinning, and passed through a column (DCM: MeOH ═ 80:1) to obtain 203.8mg of the compound (9) as a yellow solid in a yield of 72.3%.
Synthesis of (3- ((6- (trifluoromethyl) -1H-indol-4-) amino) phenyl) aminoacetic acid (N14)
Compound (9) (100mg,0.255mmol) was dissolved in ethanol and water (3:3mL), and sodium hydroxide (30.6mg,0.765mmol) was added thereto, the mixture was stirred at room temperature for 12 hours, the reaction mixture was stirred with ethanol under reduced pressure, the pH was adjusted to about 4 with 1N hydrochloric acid, EA was extracted, dried over anhydrous magnesium sulfate, and the mixture was applied to a column (DCM: MeOH ═ 30:1) to obtain compound N14 as a yellow solid. The yield is 42.3%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.12(s,1H,indazole-NH),8.36(s,1H,indazole-H3),7.33-6.61(m,5H,Ar-H),6.41(s,1H,Ar-H),6.27(s,1H,NH),4.36(d,2H,J=5.8Hz,benzyl-CH2),3.75(s,2H,NHCH2).13C-NMR(100MHz,d6-DMSO,ppm):δ173.0,148.8,143.4,140.6,140.4,129.4,128.9,124.5,120.0,115.6,115.1,111.6,111.0,95.2,93.6.ESI-MS:365.12[M+H].
example 7 Synthesis of Compounds N15 and N16 of the invention
Synthesis of Compound (11)
The starting material (5b) (200.0mg,1.0mmol) and the starting material (10) (181.2mg,1.2mmol) were dissolved in DCM (10mL), DHP (354.2mg,1.4mmol) was added dropwise, trifluoroacetic acid (74.5uL,1.0mmol) was added dropwise, and the reaction was refluxed at 40 ℃ for 12 hours. The reaction was filtered, spun-dried, and passed through a column (DCM 60mL, DCM: MeOH ═ 50: 1) to give compound (11)278.8mg of a yellow solid in 83.0% yield.
Synthesis of Compound (N15)
Compound (11) (200mg,0.595mmol) was dissolved in ethanol and water (1:1), ammonium chloride (16.5mg,0.3mmol) was added thereto, iron powder (166.7mg,2.98mmol) was added in portions, reaction was carried out at 80 ℃ for 30 minutes, the reaction solution was filtered while hot, the solvent was dried under reduced pressure, and column-packed (DCM: MeOH ═ 30:1) was passed through to obtain 155.9mg of compound (N15) as a pale yellow solid with a yield of 85.6%.
Synthesis of Compound (13)
The raw material (N15) (68.3mg,0.223mmol) and the raw material (12) (30.0mg,0.268mmol) were dissolved in DCM (2mL), DHP (79.1mg,0.312mmol) was added dropwise, trifluoroacetic acid (16.6uL,0.223mmol) was added dropwise, and the reaction was refluxed at 40 ℃ for 12 hours. The reaction was filtered, spun-dried, and passed through a column (DCM: MeOH: 100:1) to give compound (13)57.3mg of a pale yellow solid in 66.2% yield.
Synthesis of 3- ((3- ((6- (trifluoromethyl) -1H-indol-4-) amino) phenyl) amino) -1-cyclohexanol (N16)
Compound (13) (55mg,0.137mmol) was dissolved in ethanol (1mL), placed at 0 ℃, sodium borohydride (76.6mg,0.684mmol) was added, the mixture was warmed to room temperature and stirred for reaction for 12 hours, the reaction solution was cooled to 0 ℃, acetone (2mL) was added to quench the excess sodium borohydride, and the reaction solution was spin-dried over a column (DCM: MeOH ═ 20:1) to give a pale yellow solid compound (N16). The yield is 68.7%; a light yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.13(s,1H,indazole-NH),8.37(s,1H,indazole-H),7.32(t,1H,J=5.2Hz,NH),7.01-6.42(m,5H,Ar-H),6.18(s,1H,Ar-H),4.59(s,1H,NH),4.42(s,1H,OH),4.35(d,2H,J=5.6Hz,benzyl-CH2),3.57(t,1H,J=4.1Hz,CH),2.51(d,1H,J=1.8Hz,CH),1.66-0.89(m,8H,CH2).13C-NMR(100MHz,d6-DMSO,ppm):δ148.5,143.4,140.5,140.4,132.8,128.7,126.8,124.1,115.1,114.7,111.5,111.4,95.0,93.7,68.3,65.3,50.0,42.8,35.6,32.2,19.6.ESI-MS:405.19[M+H].
example 8 Synthesis of Compounds N17, N18, N19 and N20 of the invention
Synthesis of Compound 15
Compound 14(2.47g,24.46mmol) was dissolved in anhydrous methanol (30mL) and SOCl was added dropwise under ice bath2(8.78mL,122.30mmol), heating to room temperature after the addition, stirring for 12h, spin-drying the reaction solution to obtain a crude product, namely a white solid compound 15, and directly carrying out the next step of reaction with the yield of 99%.
Synthesis of Compound 16
Compound 15(3.68g,24.46mmol) was dissolved in acetonitrile (25mL) and Et was added dropwise under ice bath3N (3.39mL,24.46 mmol). Will (Boc)2O (5.87g,26.91mmol) was dissolved in acetonitrile (5mL) and added dropwise to the reaction mixture. After the addition, the temperature is raised to room temperature and the mixture is stirred for 4 hours, then the solid in the reaction solution is filtered, the filtrate is dried by spinning, and the residue is dissolved by adding water. Extracting with EA for 3 times, mixing organic layers, washing with saturated sodium chloride aqueous solution once, drying the organic layer with anhydrous magnesium sulfate, filtering, and spin-drying to obtain crude product. The crude product was purified by column chromatography (PE: EA ═ 20:1) to give compound 16(3.00g,9.73mmol) as a pale yellow oil in 65% yield.
Synthesis of Compound 17
Compound 16(2.00g,10.64mmol) was placed in a three-necked flask, DCM was added under argon to dissolve it, and the flask was stirred at-78 ℃. After 10min DIBAL-H (2.3mL,1M) was slowly added dropwise. After the addition was completed, the mixture was stirred at-78 ℃ for 30min, and then quenched with 2mL of anhydrous methanol. After 5min, move to ice bath. 200mL of a 10% citric acid aqueous solution was added to the reaction mixture, and a solid was precipitated. Stirring in ice bath for 30min until the solid disappeared, extracting the aqueous layer with EA 3 times, combining the organic layers, washing once with saturated aqueous sodium chloride solution, and drying over anhydrous magnesium sulfate. Filtering, and spin-drying the filtrate to obtain a crude product, namely a light yellow transparent oily liquid compound 17. The next reaction step is directly carried out, and the yield is 99 percent.
Synthesis of Compound 18
Compound 5b (200mg,1.00mmol), compound 17(471mg,2.99mmol) and DHP (352mg,1.39mmol) were dissolved in DCM and TFA (74. mu.l, 1.00mmol) was added dropwise with stirring. After the addition, the temperature is raised to reflux and stirring for 12 hours, and the reaction solution is dried by spinning to obtain a crude product. The crude product was purified by column chromatography (DCM: MeOH ═ 60:1) to give compound 18(100mg,0.27mg) as an orange solid. The yield thereof was found to be 27%.
Synthesis of N- (3-methyl-azacyclobutane) -6-trifluoromethyl-1H-indol-4-amine (N17)
Compound 18(50mg,0.14mmol) was dissolved in DCM (2mL) and TFA (0.30mL,2.63mmol) was added dropwise with stirring. After the addition, the reaction solution was stirred at room temperature for 3 hours, and the crude product was obtained by spin-drying the reaction solution, which was purified by column chromatography (DCM: MeOH ═ 20:1) to obtain a yellow solid compound N17. The yield is 63.0%; a solid of earthy yellow color;1H-NMR(400MHz,d6-DMSO,ppm):δ8.31(s,1H,indazole-H),6.99(s,1H,Ar-H),6.74(t,1H,J=5.3Hz,NH),6.19(s,1H,Ar-H),3.59(m,2H,CH2),3.45-3.42(m,2H,CH2),3.28(d,2H,J=6.5Hz,benzyl-CH2),2.97-2.90(m,2H,CH andNH).13C-NMR(100MHz,d6-DMSO,ppm):δ143.5,140.6,132.6,128.8,126.8,124.1,114.9,95.0,92.9,50.7,47.0,33.9.ESI-MS:271.11[M+H].
n18, N19 and N20 were synthesized in a similar manner, except that the starting materials were changed to 19, 20 and 21. The results and characterization were as follows:
(R) -N- (pyrrole-2-methyl) -6- (trifluoromethyl) -1H-indol-4-amine (N18) yield 50.0%; a yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ8.33(s,1H,indazole-H),6.98(s,1H,NH),6.95(s,1H,Ar-H),6.65(t,1H,NH),6.22(s,1H,Ar-H),3.37-3.31(m,2H,benzyl-CH2)),3.21-3.09(m,3H,CH2and CH),2.89-2.76(m,1H,NH)1.89-1.38(m,6H,CH2).13C-NMR(100MHz,d6-DMSO,ppm):δ143.5,410.7,132.5,129.1,128.8,114.9,95.0,93.0,57.1,48.7,46.3,29.9,25.4.ESI-MS:285.13[M+H].
(R) -N- (piperidine-2-methyl) -6- (trifluoromethyl) -1H-indol-4-amine (N19) yield 57.0%; a light yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.23(s,1H,indazole-NH),8.43(s,1H,indazole-H3),7.05(s,2H,NH and Ar-H),6.30(s,1H,Ar-H),3.51-3.18(m,6H,CH2and NH)1.92-1.43(m,6H,CH2).ESI-MS:399.14[M+H].
(S) -N- (piperidine-2-methyl) -6- (trifluoromethyl) -1H-indol-4-amine (N20) yield 57.0%; a light yellow solid;1H-NMR(400MHz,d6-DMSO,ppm):δ13.26(s,1H,indazole-NH),8.48(s,1H,indazole-H),7.14(t,1H,J=5.5Hz,NH),7.06(s,1H,Ar-H),6.30(s,1H,Ar-H),3.56-3.40(m,2H,CH),2.90-2.85(m,2H,benzyl-CH2),1.92(m,1H,NH)1.70-1.44(m,5H,CH2),1.12(m,2H,CH2)13C-NMR(100MHz,d6-DMSO,ppm):δ142.9,140.6,132.9,129.0,115.3,100.0,96.0,93.2,55.2,45.9,44.5,27.1,22.7,22.2.ESI-MS:299.15[M+H].
EXAMPLE 9 inhibitory Activity of Compounds of the present invention on IDO protein
The recombinant human IDO protein is obtained by expressing through escherichia coli and purifying through nickel affinity chromatography. The compound has IDO inhibitory activity, and L-tryptophan is used as a substrate. The test compound was dissolved in 10% DMSO to prepare a dilution. 5uL of the dilution was added to 100. mu.L of the reaction. The 100. mu.L reaction contained 0.5% DMSO, 40nmol/LIDO, 900. mu. mol/L L-tryptophan, and other reaction co-products (potassium phosphate buffer, ascorbic acid, catalase, methylene blue). The reaction mixture was incubated at 37 ℃ for 180 minutes and stopped by the addition of trichloroacetic acid. The inhibitory activity of the compounds on IDO was evaluated by measuring the concentration of N-formyl kynurenine produced at 321nm using a Tecan Infinite M1000 microplate reader. The negative control was 5. mu.L of buffer instead of IDO. Clinical stage III IDO inhibitor INCB024360 was used as positive control to verify whether the IDO activity detection system established in this experiment was effective.
Three replicates of wells were set for each concentration. Data analysis was performed using software Graphpad Prism. Absorbance (A) in the reaction solution containing no test compoundt) Defined as 100% activity. Absorbance (A) in the reaction solution containing no IDOb) Defined as 0% activity. For the test compounds, the activity is calculated as: % activity ═ A-Ab)/(At-Ab)]X 100, wherein A is the absorbance of the reaction solution containing the test compound. The formula for calculating the inhibition rate is as follows: % inhibition is 100-% activity.
By the above experimental method, the inhibitory activity against IDO of some of the compounds of the present invention was tested. The inhibitory activity of specific compounds at concentrations of 1. mu.M, 10. mu.M and 100. mu.M is shown in Table 1.
Wherein A represents that the inhibition rate is more than 90%, B represents that the inhibition rate is 70-89%, and C represents that the inhibition rate is 40-69%; d represents that the inhibition rate is 10-39%, E represents that the inhibition rate is less than 10%; the inhibition of the positive control at a concentration of 0.05. mu.M was 46%.
TABLE 1 inhibitory Activity of the Compounds of the present invention on IDO
The structure-activity relationship shows that: when R is1The effect on activity was in turn: halogen element>Alkane(s)>A halogenated alkane; r2When the structure is longer, the activity is obviously reduced; r2Preferably a substituted benzene ring or a substituted aliphatic ring, and containing polar groups, e.g. OH, COOH, NH2,NO2When the compound is used, the activity of the compound is obviously increased.
Experiments prove that the 1H-indazole derivative provided by the invention has an excellent inhibiting effect on IDO, and can be used for preventing and/or treating various diseases, such as Alzheimer disease, cataract, infection related to cellular immune activation, autoimmune diseases, AIDS, cancer, depression or tryptophan metabolic disorder and the like.
Claims (10)
1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (I):
wherein,
R1selected from H, halogen, C1~C6Alkyl or C1~C6A haloalkyl group;
R2is selected from the group consisting ofSubstituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl, each of said substituted aryl, heteroaryl, cycloalkyl or heterocyclyl being independently substituted with one or more substituents selected from the group consisting of halogen, -NH2、-(CH2)aOH, -COOH, nitro, C1~C6Alkyl radical, C1~C6Haloalkyl, -CONH-R3or-NH-R4Substituted with the substituent(s);
R3is selected from C1~C6An alkyl group;
R4(ii) select-CH2COOH or 5-6 membered cycloalkyl or C1~C6Alkyl-substituted cycloalkyl groups;
a is 0 or 1.
2. The compound of claim 1, wherein: the R is1Selected from H, Cl, -Br, CF3、-CHX2、-CH2X or-CH3。
3. The compound of claim 1, wherein: said C is1~C6The alkyl group is selected from methyl.
4. The compound of claim 1, wherein: said C is1~C6Haloalkyl is trifluoromethyl.
5. The compound of claim 1, wherein: the aryl is selected from phenyl, the heteroaryl is selected from benzothiophene, the cycloalkyl is selected from cyclohexyl, and the heterocyclic group is selected from a 4-6-membered nitrogen heterocyclic group.
6. The compound according to any one of claims 1-5, wherein: the R is2Selected from one of the following groups:
7. the compound of claim 1, wherein: the compound is selected from one of the following compounds:
8. the use of a compound of any one of claims 1 to 7, a compound of formula (II), or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, for the manufacture of a medicament which is an IDO inhibitor,
R1as defined in any one of claims 1 to 4.
9. Use according to claim 8, characterized in that: the drug is a drug for preventing and/or treating Alzheimer's disease, cataract, infection related to cellular immune activation, autoimmune disease, AIDS, cancer, depression or tryptophan metabolism disorder.
10. A pharmaceutical composition characterized by: the compound or the pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable auxiliary materials.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610831550.7A CN107840826B (en) | 2016-09-19 | 2016-09-19 | 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor |
PCT/CN2016/099845 WO2017133258A1 (en) | 2016-02-04 | 2016-09-23 | 1h-indazole derivative and use thereof as ido inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610831550.7A CN107840826B (en) | 2016-09-19 | 2016-09-19 | 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107840826A true CN107840826A (en) | 2018-03-27 |
CN107840826B CN107840826B (en) | 2021-07-09 |
Family
ID=61656406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610831550.7A Active CN107840826B (en) | 2016-02-04 | 2016-09-19 | 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107840826B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108689937A (en) * | 2017-04-10 | 2018-10-23 | 西华大学 | Indazole compound and application thereof in preparation of IDO inhibitor medicines |
CN108689938A (en) * | 2017-04-10 | 2018-10-23 | 西华大学 | Polysubstituted indazoles and their use as IDO inhibitors |
CN111285808A (en) * | 2018-12-07 | 2020-06-16 | 西华大学 | Indazole compound substituted by 4-position aromatic heterocycle and application thereof as IDO/TDO dual inhibitor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298460A (en) * | 2010-12-14 | 2013-09-11 | 电泳有限公司 | Casein kinase 1delta (ck1delta) inhibitors |
WO2015123365A1 (en) * | 2014-02-11 | 2015-08-20 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
WO2016071293A2 (en) * | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
CN107033087A (en) * | 2016-02-04 | 2017-08-11 | 西华大学 | 1H- indazole -4- aminated compounds and its purposes as IDO inhibitor |
-
2016
- 2016-09-19 CN CN201610831550.7A patent/CN107840826B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298460A (en) * | 2010-12-14 | 2013-09-11 | 电泳有限公司 | Casein kinase 1delta (ck1delta) inhibitors |
WO2015123365A1 (en) * | 2014-02-11 | 2015-08-20 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
WO2016071293A2 (en) * | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
CN107033087A (en) * | 2016-02-04 | 2017-08-11 | 西华大学 | 1H- indazole -4- aminated compounds and its purposes as IDO inhibitor |
Non-Patent Citations (1)
Title |
---|
REGISTRY: ""RN1525839-79-5等"", 《STN COLUMBUS》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108689937A (en) * | 2017-04-10 | 2018-10-23 | 西华大学 | Indazole compound and application thereof in preparation of IDO inhibitor medicines |
CN108689938A (en) * | 2017-04-10 | 2018-10-23 | 西华大学 | Polysubstituted indazoles and their use as IDO inhibitors |
CN108689938B (en) * | 2017-04-10 | 2021-07-30 | 西华大学 | Polysubstituted indazoles and their use as IDO inhibitors |
CN108689937B (en) * | 2017-04-10 | 2021-09-17 | 西华大学 | Indazole compound and application thereof in preparation of IDO inhibitor medicines |
CN111285808A (en) * | 2018-12-07 | 2020-06-16 | 西华大学 | Indazole compound substituted by 4-position aromatic heterocycle and application thereof as IDO/TDO dual inhibitor |
CN111285808B (en) * | 2018-12-07 | 2023-06-23 | 西华大学 | 4-aromatic heterocycle substituted indazole compound and application thereof as IDO/TDO dual inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CN107840826B (en) | 2021-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019240616B2 (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
TWI766882B (en) | Novel compounds | |
CN107033087B (en) | 1H-indazole-4-amine compounds and use thereof as IDO inhibitors | |
CN105358550B (en) | Histone deacetylase inhibitors | |
DK2152692T3 (en) | EXTERNAL anti-cancer activity | |
JP6117430B2 (en) | Novel compounds as selective histone deacetylase inhibitors and pharmaceutical compositions containing the same | |
WO2011007819A1 (en) | Pharmaceutical product containing lactam or benzene sulfonamide compound | |
CA2920815A1 (en) | Inhibitors of plasma kallikrein | |
PT2928867T (en) | Pyridine-2-amides useful as cb2 agonists | |
TW202017916A (en) | Novel bradykinin b2 receptor antagonists and the use thereof | |
KR20110105792A (en) | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
CN107840826B (en) | 1H-indazole derivatives and application thereof as IDO (intermediate bonded oxygen) inhibitor | |
CN108689937B (en) | Indazole compound and application thereof in preparation of IDO inhibitor medicines | |
RU2709810C2 (en) | Pyrazolo[3,4-c]pyridine derivatives | |
JP7397072B2 (en) | 2,6-dimethyl-N-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-N-[(pyridine -4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivative | |
JP2023529570A (en) | N-cyanopyrrolidines with activity as USP30 inhibitors | |
CA2887420C (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
CN106986874B (en) | (1H-pyrazolo [3,4-d ] pyrimidine) -4-amino derivatives and their use as IDO inhibitors in the manufacture of medicaments | |
CN107118209A (en) | Pyrido [3,4-b ] indolylurea compounds and application thereof as IDO (intermediate compound) inhibitor | |
RU2821520C2 (en) | N-((het)arylmethyl)-heteroaryl-carboxamide compounds as plasma kallikrein inhibitors | |
WO2020219808A1 (en) | Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases | |
CN113527261A (en) | Pyridone or pyrimidone derivative and preparation method and application thereof | |
JP2023541309A (en) | Piperazine derivatives, their production methods and their uses | |
NZ770256B2 (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |